Ophthalmic

West Point Optical Group, LLC and Verséa Ophthalmics, Inc. Announce Partnership Supply Agreement for  BIOVANCE®and BIOVANCE® 3L Ocular

Retrieved on: 
Wednesday, April 3, 2024
Health, Optical, Surgery, WPOG, Extracellular matrix, Allotransplantation, Partnership, Patient, Wound healing, Pearle Vision, OD, Ophthalmic, Telescopic sight

BIOVANCE® and BIOVANCE® 3L Ocular, which are single-layer and three-layer (3L) allografts, respectively, are intended for use as a biological membrane covering that provides an extracellular matrix.

Key Points: 
  • BIOVANCE® and BIOVANCE® 3L Ocular, which are single-layer and three-layer (3L) allografts, respectively, are intended for use as a biological membrane covering that provides an extracellular matrix.
  • BIOVANCE® 3L Ocular is acellular and consists of three layers of amniotic basement membrane that supports treatment of advanced ocular surface disease.
  • As a barrier membrane, BIOVANCE® 3L Ocular is intended to protect the underlying tissue and preserve tissue plane boundaries.
  • “We are excited to partner with Verséa Ophthalmics allowing our eye care professionals to deliver the benefits of BIOVANCE® and BIOVANCE® 3L Ocular products to their patients,” said John Womack, OD, West Point Optical Group’s Chief Medical Officer.

Azura Ophthalmics to Present New Data Supporting the Potential of AZR-MD-001 to be the First Ophthalmic Keratolytic for Ocular Surface Diseases

Retrieved on: 
Thursday, March 28, 2024
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Research, CLD, Refractive surgery, ASCRS, Patient, Telecanthus, ARVO, University, Cataract, Abstract, Eyelid, Detail, Society, University of California, Irritation, Safety, MGD, Pain, Ophthalmic, Pharmaceutical industry

Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a potential new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced multiple presentations highlighting positive efficacy and safety data from Phase 2 studies of the company’s lead drug candidate, AZR-MD-001, in Meibomian Gland Dysfunction (MGD).

Key Points: 
  • Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a potential new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced multiple presentations highlighting positive efficacy and safety data from Phase 2 studies of the company’s lead drug candidate, AZR-MD-001, in Meibomian Gland Dysfunction (MGD).
  • This includes new, long-term data at ASCRS of the company’s lead drug candidate, AZR-MD-001, showing improvement in both signs and symptoms in MGD and Contact Lens Discomfort (CLD).
  • “Together, the data set we are presenting at these prestigious conferences show multiple potential patient benefits and mild, transient side effects in a topical medicine, supporting the potential of AZR-MD-001 as an entirely new approach targeting the underlying cause of many ocular surface diseases,” said Marc Gleeson, Chief Executive Officer of Azura.
  • This causes inflammatory ocular surface conditions, ocular surface dryness, pain, irritation, and reduced quality of vision.

Senior Ophthalmology Executive Thomas A. (Tom) Dunlap Joins WaveFront Dynamics Inc. as an Independent Member of the Board of Directors to Support the Company’s Ongoing Commercialization and Broader Strategic Initiatives

Retrieved on: 
Wednesday, March 20, 2024
Venture Capital, Medical Devices, Health, Professional Services, Optical, Wavefront, Coherence, WDI, Patient, Ophthalmic, University, Bausch & Lomb, MBA, Tom, Multimedia, Physician, Management

View the full release here: https://www.businesswire.com/news/home/20240320844399/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240320844399/en/
    Senior Ophthalmology Executive Thomas A.
  • (Tom) Dunlap joins WaveFront Dynamics Inc. as an Independent member of the Board of Directors to support the company’s ongoing commercialization and broader strategic initiatives.
  • (Photo: Business Wire)
    “We are pleased to have Tom Dunlap join our Board of Directors.
  • He brings experience as an Independent Board member, Non-Executive Director, and Chairman of the Board with private Ophthalmic medical device companies.

MediPrint® Ophthalmics Announces Successful Completion of Its Phase 2b Glaucoma Clinical Study with Positive Results.

Retrieved on: 
Wednesday, March 6, 2024
Research, Medical Devices, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, Optical, Science, Ocular hypertension, IOP, Ophthalmic, Lens, 3D, Safety, Contact, Patient, Phase, Telescopic sight

MediPrint® Ophthalmics , a clinical-stage ocular drug delivery platform technology focused on transforming ocular drug delivery, announces the completion of its Glaucoma SIGHT-2, Phase 2b study.

Key Points: 
  • MediPrint® Ophthalmics , a clinical-stage ocular drug delivery platform technology focused on transforming ocular drug delivery, announces the completion of its Glaucoma SIGHT-2, Phase 2b study.
  • The Phase IIb trial was an active-controlled, randomized, dose-finding, multi-center study, evaluating the Company’s lead candidate (LL-BMT1) versus a control group on bimatoprost 0.01% ophthalmic solution.
  • SIGHT-2 study evaluated safety and efficacy of LL-BMT-1 in 28 patients diagnosed with open-angle Glaucoma for three weeks.
  • “The successful completion of the study is an important milestone as it validates our company’s technology and will help address significant unmet need for patients suffering from Glaucoma or Ocular Hypertension.

HOYA Vision Care Announces New iD LifeStyle® 4 Progressive Lenses with 3D Binocular Vision™ Technology

Retrieved on: 
Tuesday, March 5, 2024
Lifestyle (Australian TV channel), VSP, Binocular vision, ID, Visual acuity, Ophthalmic, Patient, Telescopic sight

LEWISVILLE, Texas, March 5, 2024 /PRNewswire/ -- Ophthalmic lens technology leader HOYA Vision Care announced the launch of iD LifeStyle® 4 with 3D Binocular Vision™ technology, the newest progressive lens in its award-winning iD LifeStyle® family, available to order on March 13. Building upon HOYA's longstanding reputation in the progressive lens category, the addition of 3D Binocular Vision technology delivers faster adaptation thanks to 3 times less peripheral distortion1.

Key Points: 
  • LEWISVILLE, Texas, March 5, 2024 /PRNewswire/ -- Ophthalmic lens technology leader HOYA Vision Care announced the launch of iD LifeStyle® 4 with 3D Binocular Vision™ technology, the newest progressive lens in its award-winning iD LifeStyle® family, available to order on March 13.
  • "With the addition of new 3D Binocular Vision technology, patients will enjoy a much better visual experience from the outset.
  • Eye care providers can confidently prescribe iD LifeStyle 4 knowing they will have happier patients who can adapt to their progressive lenses faster."
  • New for iD LifeStyle 4 is 3D Binocular Vision technology which reduces unwanted prismatic (i.e., swim) effects in the near-range peripheral vision.

Azura Ophthalmics Announces Positive Results from Phase 2 Clinical Trial of AZR-MD-001 in Patients with Contact Lens Discomfort

Retrieved on: 
Monday, December 18, 2023
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Contact lens, CLD, Meibomian gland dysfunction, Safety, Gland, Lens, Eyelid, Irritation, AZR, Dry, Patient, FDA, Ophthalmic, Fluorescein, Contact, MGD, MGS, Pain, Quality of life, Telescopic sight, Azura

This is the second positive Phase 2 study of AZR-MD-001 to demonstrate statistically significant improvements across multiple sign and symptom endpoints in patients with MGD.

Key Points: 
  • This is the second positive Phase 2 study of AZR-MD-001 to demonstrate statistically significant improvements across multiple sign and symptom endpoints in patients with MGD.
  • “MGD is the root cause of many downstream ocular surface conditions that impact quality of life and vision for patients, including Contact Lens Discomfort.
  • This leads to several downstream ocular surface symptoms including dryness, pain, irritation, reduced quality of vision, and Contact Lens Discomfort.
  • “MGD is one of the causes of Contact Lens Discomfort, and many patients give up on wearing contact lenses altogether due to the irritation they experience.

Global Ophthalmic Imaging Equipment Pipeline Research Report 2023: Analysis by Stages of Development, Segments, Region, Regulatory Path and Key Companies - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 14, 2023
Health, Optical, Development, Clinical trial, Ophthalmic, Segment

The "Ophthalmic Imaging Equipment Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Ophthalmic Imaging Equipment Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies" report has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive coverage of the development landscape of Ophthalmic Imaging Equipment, offering insights into various critical aspects.
  • It begins by presenting an extensive overview of Ophthalmic Imaging Equipment products currently under development, providing valuable insights into the latest innovations and advancements in this field.
  • Furthermore, the report offers essential clinical trial data related to ongoing trials specific to pipeline products, providing insights into the clinical development progress and outcomes.

Renowned Philadelphia Oculoplastic Surgeon, Dr. John J.W. Lee, Named a 2023 Top Patient Rated Doctor by Find Local Doctors

Retrieved on: 
Wednesday, November 15, 2023
Specialization, Eyelid, Ophthalmic, Patient, Multimedia, Hospital, Society, Wills Eye Hospital, Dentistry, Nursing, Blepharoplasty

BRYN MAWR, Pa., Nov. 15, 2023 /PRNewswire-PRWeb/ -- Dr. John J.W. Lee, a highly-credentialed oculoplastic and reconstructive surgeon in the Philadelphia, PA, area has recently been recognized as a Top Patient Rated Doctor by Find Local Doctors. His patient-centered approach and expert knowledge in oculoplastic procedures have fostered a large volume of outstanding reviews from his patients across multiple online sources. Such superior ratings have led Find Local Doctors, a credible online directory of medical providers, to honor him with this award. Dr. Lee is a skilled oculoplastic surgeon who is highly sought-after for his specialization in reconstructive, revisional and cosmetic surgery of the eyes and surrounding tissue. Dr. Lee is known for exceptional Blepharoplasty (Eyelid Surgery) outcomes. He also operates a full-service med spa, Lux Skin Lasers, which offers the latest non-surgical treatments in facial rejuvenation. Renowned for his artistic approach and meticulous attention to detail, Dr. Lee holds elite qualifications and experience in his field. He has spent 15+ years performing over 12,000+ eyelids surgeries and has honed and evolved his surgical techniques. Using the latest advancements and cutting-edge technology at his clinic, Dr. Lee passionately pursues new innovative techniques to produce beautiful results with minimal downtime for his patients.

Key Points: 
  • Dr. Lee is known for his expertise in Blepharoplasty (Eyelid Surgery) and exceptional outcomes with Facial Fillers and Neuromodulators.
  • Lee, a highly-credentialed oculoplastic and reconstructive surgeon in the Philadelphia, PA, area has recently been recognized as a Top Patient Rated Doctor by Find Local Doctors .
  • Such superior ratings have led Find Local Doctors, a credible online directory of medical providers, to honor him with this award.
  • Renowned for his artistic approach and meticulous attention to detail, Dr. Lee holds elite qualifications and experience in his field.

EyeCare Partners Highlights Clinical and Research Leadership at the American Academy of Ophthalmology (AAO) 2023 in San Francisco

Retrieved on: 
Thursday, November 2, 2023
General Health, Optical, Health, Practice Management, Partner, MEB, American Academy of Ophthalmology, Ophthalmic, MSCE, Education, Booth, Physician, Moscone Center, Medicine, Consultant, AAO, Safety, MBA, Research, OWL, Injection (medicine), American Association of University Professors, Rejuvenation, American Academy, Doctor of Pharmacy, ECP, EPIC, Patient, Pharmaceutical industry, Nursing, Ophthalmology

EyeCare Partners (ECP), the nation’s leading provider of clinically integrated eye care, today announced key leadership updates and research in ophthalmic innovation, advanced by ECP physicians, at American Academy of Ophthalmology (AAO) 2023.

Key Points: 
  • EyeCare Partners (ECP), the nation’s leading provider of clinically integrated eye care, today announced key leadership updates and research in ophthalmic innovation, advanced by ECP physicians, at American Academy of Ophthalmology (AAO) 2023.
  • The annual meeting takes place Friday, Nov. 3, through Monday, Nov. 6, at the Moscone Center in San Francisco.
  • “Our engagement at AAO 2023 is underpinned by our world-class team of physicians advancing eye care through their commitment to clinical research and education,” said Dr. Daniel Miller, Ophthalmology Division President and Executive Medical Officer, EyeCare Partners.
  • A number of EyeCare Partners’ physicians are leading learning sessions and have research contributions to be announced at AAO 2023.

Implandata Announces Appointment of New Members Dr. Adrienne Graves and Jan Willem de Cler to Join Board of Directors

Retrieved on: 
Tuesday, October 24, 2023
Himalayan Cataract Project, FCI, Glaucoma, Emeritus, GE HealthCare, General Electric, IDE, Alcon, Marketing, FFB, Ophthalmic, ASCRS, Ophthalmology, OWL, Cataract, Carl Zeiss Meditec, University, Nyenrode Business University, Research, Business administration, ISCB Senior Scientist Award, FDA, Refractive surgery, RD, MBA, B2B, Society, Private equity, FMP, Senior advisor, Telemetry, DAX, SAN, Management, Benelux, Health care, Residence

HANNOVER, Germany, Oct. 24, 2023 /PRNewswire-PRWeb/ -- A visual scientist by training and a global industry leader in ophthalmology, Dr. Adrienne Graves brings extensive experience to Implandata. As the former CEO of Santen Inc., she successfully established a strong global presence, bringing multiple ophthalmic products through development to approval and commercialization and leading global teams through successful acquisitions and partnerships. Prior to Santen, she spent 9 years at Alcon, joining as Senior Scientist to establish Alcon's first Retinal Electrophysiology Laboratory. She progressed through roles of increasing responsibility in research and development, including directing clinical development in multiple therapeutic areas and serving as Director of International Ophthalmology. Dr. Graves currently serves as a director on the boards of various ophthalmic pharmaceutical and health-tech companies. She serves on the Foundation Boards of the American Society of Cataract and Refractive Surgery (ASCRS) Foundation, Glaucoma Research Foundation, American Academy of Ophthalmology Foundation (Emeritus), Retina Global, Himalayan Cataract Project, Foundation Fighting Blindness (FFB) and the RD (Retinal Degeneration) Fund. Dr. Graves also co-founded Glaucoma 360 and OWL (Ophthalmic World Leaders, formerly Ophthalmic Women Leaders).

Key Points: 
  • Jan Willem de Cler will also take over responsibility as Chairman of the Board.
  • HANNOVER, Germany, Oct. 24, 2023 /PRNewswire-PRWeb/ -- A visual scientist by training and a global industry leader in ophthalmology, Dr. Adrienne Graves brings extensive experience to Implandata.
  • Prior to Santen, she spent 9 years at Alcon, joining as Senior Scientist to establish Alcon's first Retinal Electrophysiology Laboratory.
  • Jan Willem studied Business Administration at Nijenrode University in the Netherlands and the University of Oregon, USA where he accomplished his MBA.